Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H27NO4 |
| Molecular Weight | 345.4327 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CCNC[C@@H](O)COC2=CC(C)=CC=C2)C=C1OC
InChI
InChIKey=HXLAFSUPPDYFEO-QGZVFWFLSA-N
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3/t17-/m1/s1
| Molecular Formula | C20H27NO4 |
| Molecular Weight | 345.4327 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. | 2007-07-12 |
|
| Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. | 2007-07 |
|
| Determination of bevantolol enantiomers in human plasma by coupled achiral-chiral high performance-liquid chromatography. | 2007-07 |
|
| Chiral purity test of bevantolol by capillaryelectrophoresis and high performance liquid chromatography. | 2006-09 |
|
| Effect of beta-blocker therapy on myocardial perfusion defects in thallium-201 scintigraphy in patients with dilated cardiomyopathy. | 2005 |
|
| Atypical cardiostimulant beta-adrenoceptor in the rat heart: stereoselective antagonism by bupranolol but lack of effect by some bupranolol analogues. | 2003-08 |
|
| Effect of beta-blockers on insulin resistance in patients with dilated cardiomyopathy. | 2003-08 |
|
| Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy. | 2002-12 |
|
| Use of thallium-201 myocardial scintigraphy for the prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy. | 2002-12 |
|
| Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems. | 2002-08 |
|
| The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. | 2001-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:27:33 GMT 2025
by
admin
on
Mon Mar 31 23:27:33 GMT 2025
|
| Record UNII |
34P43RW460
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135531-40-7
Created by
admin on Mon Mar 31 23:27:33 GMT 2025 , Edited by admin on Mon Mar 31 23:27:33 GMT 2025
|
PRIMARY | |||
|
34P43RW460
Created by
admin on Mon Mar 31 23:27:33 GMT 2025 , Edited by admin on Mon Mar 31 23:27:33 GMT 2025
|
PRIMARY | |||
|
36690919
Created by
admin on Mon Mar 31 23:27:33 GMT 2025 , Edited by admin on Mon Mar 31 23:27:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
